Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 08:53:05 +0200Fri, 12 Jul 2024 14:44:00 +0200Opinion/decision on a Paediatric investigation plan (PIP): Taltz, ixekizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0049/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001050-pip02-18-m02Opinion/decision on a Paediatric investigation plan (PIP): Taltz, ixekizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0049/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001050-pip02-18-m02Fri, 12 Jul 2024 14:44:00 +0200Human medicine